Amoxi-Clav is a combinatoin preparation consisting of a broad-spectrum antibiotic (amoxycillin) and a beta-lactamases inhibitor (clavulanic acid). Amoxycillin has a bactericidal action: it inhibits synthesis of the bacterial cell-wall during the growth phase by competitive Inhibition of transpeptidases.
Clavulanic acid itself possesses only slight antibacterial activity but it binds beta-lactamases irreversibly, thus inhibiting the breakdown of amoxycillin. The antibacterial spectrum of Amoxi-Clav includes the following clinically important microorganisms;
Staphylococci (penicillin-sensitive and penicillin-resistant), Streptococci, Enterococci, Neisseriae, Branhamella catarrha lis, Enterobacteria (E. coli, Salmonellae, Shigellae, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumoniae), Haemophilus, influenzae, Nocardiae, Leptospirae, anaerobic coca, Bacteroides spp. and Fusobacterium. The following microorganisms are resistant or partly resistant: Pseudomonas aeruginosa, Enterobacter, Serratia, Proteus rettgeri, Proteus morganii, Providencia, methicillin- resistant Staphylococci, Mycoplasms, Chlamydiae and Rickettsiae.